Regeneron Pharmaceuticals Inc. buy SVB Securities
Summary
This prediction ended on 28.03.24 with a price of €895.00. The BUY prediction by SVB_Securities finished with a performance of 16.25%. SVB_Securities has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Regeneron Pharmaceuticals Inc. | 1.775% | 1.775% | 32.041% |
iShares Core DAX® | 2.749% | 4.620% | 17.121% |
iShares Nasdaq 100 | 0.470% | -0.331% | 37.776% |
iShares Nikkei 225® | -2.930% | -5.556% | 12.185% |
iShares S&P 500 | 0.679% | 0.631% | 28.996% |
Comments by SVB_Securities for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
In the thread Trading Regeneron Pharmaceuticals Inc.